Recent Updates
Recently added Catalysts
ACRS Positive Sentiment

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

Thursday, February 9, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, will participate in the Virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 9:20 AM ET. The management team will conduct a fireside chat, which can be accessed via the Events page on Aclaris' website. Aclaris specializes in developing novel drug candidates for immuno-inflammatory diseases, aiming to address unmet medical needs.
Price reaction · baseline $13.72 (2023-02-08 close) · hit after-hours · clean, no other ACRS news in the window
day 0 close · peak
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Aclaris Therapeutics is participating in a prominent biopharma conference.
  • The company is focused on innovative treatments for immuno-inflammatory diseases.
  • The webcast will be accessible for 30 days, increasing visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis

Full Press Release Details

WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET.
A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Therapeutics Contact:

Frequently Asked Questions

When will Aclaris participate in the SVB Securities conference?

Aclaris will participate on February 14, 2023, at 9:20 AM ET.

How can I access the Aclaris fireside chat webcast?

The webcast can be accessed via the 'Events' page on Aclaris' website.

What is the focus of Aclaris Therapeutics?

Aclaris focuses on developing novel drugs for immuno-inflammatory diseases.

Will the webcast be available after the event?

Yes, the webcast will be archived for at least 30 days.

Who should be contacted for investor relations at Aclaris?

Contact the Vice President of Investor Relations at rdoody@aclaristx.com.

ShareAdd on Google
Tags: ACRS Viatris Investor Conferences Healthcare Aclaris Therapeutics biopharma conference immuno-inflammatory diseases drug candidates
Last updated: Feb 9, 2023

Biotech snapshot

Cash runway
$171M liquidity · $7M/mo burn
~25 mo
Minimal dilution risk
Lead asset
ATI-045Phase 2
Atopic Dermatitis →

Catalyst track record

+181%
best trade around ACRS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ACRS.

See every catalyst's timing & PoA →